Sadr-Nabavi, A., J. Ramser, J. Volkmann, J. Naehrig, F. Wiesmann, B. Betz, H. Hellebrand, S. Engert, S. Seitz, R. Kreutzfeld, T. Sasaki, N. Arnold, R. Schmutzler, M. Kiechle, D. Niederacher, N. Harbeck, E. Dahl and A. Meindl: Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker. In: International Journal of Cancer 124, 7, 1727-1735 (2009).
The Max Planck Society does not take any responsibility for the content of this export.